What changed: Triple-negative breast cancer

Indication page →

Every dated change on the records linked to Triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone5This record1

FollowWatch this record and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-23This recordTriple-negative breast cancer
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 2

2022 · 1

2022MilestoneTriple-negative breast cancer
FDA grants accelerated approval to adjuvant olaparib for germline BRCA-mutated, HER2-negative, high-risk early breast cancer
Based on OlympiA, with three-year invasive disease-free survival of 85.9% versus 77.1%.

2021 · 1

2021MilestoneTriple-negative breast cancer
FDA approves pembrolizumab as neoadjuvant plus chemotherapy then adjuvant monotherapy for high-risk early-stage TNBC
Based on KEYNOTE-522, which showed a pathological complete response of 63% versus 56%.

2020 · 1

2020MilestoneTriple-negative breast cancer
FDA grants accelerated approval to pembrolizumab plus chemotherapy for PD-L1 CPS 10 or more metastatic TNBC
Based on KEYNOTE-355, which gave a progression-free survival hazard ratio of 0.65; converted to full approval in July 2021 on final overall survival of 23.0 versus 16.1 months.